| Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC SS Ramalingam, J Vansteenkiste, D Planchard, BC Cho, JE Gray, Y Ohe, ... New England Journal of Medicine 382 (1), 41-50, 2020 | 2032 | 2020 |
| JNJ-61186372 (JNJ-372), an EGFR-cMet bispecific antibody, in EGFR-driven advanced non-small cell lung cancer (NSCLC). EB Haura, BC Cho, JS Lee, JY Han, KH Lee, RE Sanborn, R Govindan, ... Journal of Clinical Oncology 37 (15_suppl), 9009-9009, 2019 | 98 | 2019 |
| Amivantamab (JNJ-61186372), an anti-EGFR-MET bispecific antibody, in patients with EGFR exon 20 insertion (exon20ins)-mutated non-small cell lung cancer (NSCLC). K Park, T John, SW Kim, JS Lee, CA Shu, DW Kim, S Viteri Ramirez, ... Journal of Clinical Oncology 38 (15_suppl), 9512-9512, 2020 | 71 | 2020 |
| A phase II trial of the pan‐HER inhibitor poziotinib, in patients with HER2‐positive metastatic breast cancer who had received at least two prior HER2‐directed regimens … YH Park, KH Lee, JH Sohn, KS Lee, KH Jung, JH Kim, KH Lee, JS Ahn, ... International Journal of Cancer 143 (12), 3240-3247, 2018 | 53 | 2018 |
| Quantitative comparison between crowd models for evacuation planning and evaluation V Viswanathan, CE Lee, MH Lees, SA Cheong, PMA Sloot The European Physical Journal B 87, 1-11, 2014 | 37 | 2014 |
| Randomized phase III trial of irinotecan plus cisplatin versus etoposide plus cisplatin in chemotherapy-naïve Korean patients with extensive-disease small cell lung cancer DW Kim, HG Kim, JH Kim, K Park, HK Kim, JS Jang, BS Kim, JH Kang, ... Cancer Research and Treatment: Official Journal of Korean Cancer Association …, 2019 | 30 | 2019 |
| Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic … YH Park, SA Im, SB Kim, JH Sohn, KS Lee, YS Chae, KH Lee, JH Kim, ... European Journal of Cancer 86, 385-393, 2017 | 28 | 2017 |
| Safety, tolerability, and anti-tumor activity of olmutinib in non-small cell lung cancer with T790M mutation: A single arm, open label, phase 1/2 trial DW Kim, DH Lee, JY Han, J Lee, BC Cho, JH Kang, KH Lee, EK Cho, ... Lung Cancer 135, 66-72, 2019 | 26 | 2019 |
| A randomized, open-label, phase III trial of afatinib (A) vs erlotinib (E) as second-line treatment of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung … G Goss, E Felip, M Cobo, S Lu, KN Syrigos, KH Lee, E Göker, ... Annals of Oncology 25, iv426, 2014 | 25 | 2014 |
| JNJ-61186372 (JNJ-372), an EGFR-cMET bispecific antibody, in advanced non-small cell lung cancer (NSCLC): An update on phase I results BC Cho, JS Lee, JY Han, EK Cho, E Haura, KH Lee, J Bauml, ... Annals of Oncology 29, viii542, 2018 | 20 | 2018 |
| Randomized phase III trial of gefitinib or pemetrexed as second-line treatment in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy … M Ahn, J Sun, JS Ahn, S Kim, KH Lee, YJ Min, HJ Yun, H Kim, H Song, ... Journal of Clinical Oncology 29 (15_suppl), 7603-7603, 2011 | 9 | 2011 |
| PL02. 03 brigatinib vs crizotinib in patients with ALK inhibitor-naive advanced ALK+ NSCLC: First report of a phase 3 trial (ALTA-1L) R Camidge, HR Kim, M Ahn, JC Yang, J Han, J Lee, M Hochmair, JY Li, ... Journal of Thoracic Oncology 13 (10), S184-S185, 2018 | 7 | 2018 |
| Brigatinib (BRG) versus crizotinib (CRZ) in Asian versus non-Asian patients (pts) in the phase III ALTA-1L trial. MJ Ahn, HR Kim, JCH Yang, JY Han, JS Lee, MJ Hochmair, JYC Li, ... Journal of Clinical Oncology 37 (15_suppl), 9026-9026, 2019 | 6 | 2019 |
| Intracranial efficacy of brigatinib (BRG) vs crizotinib (CRZ) in the phase III ALTA-1L trial S Popat, HR Kim, MJ Ahn, JCH Yang, JY Han, MJ Hochmair, KH Lee, ... Annals of Oncology 29, viii746, 2018 | 4 | 2018 |
| YH25448, a 3rd generation EGFR-TKI, in patients with EGFR-TKI-resistant NSCLC: Phase I/II study results. BC Cho, JY Han, SW Kim, KH Lee, DW Kim, YG Lee, G Lee, JS Lee, ... Journal of Clinical Oncology 36 (15_suppl), 9033-9033, 2018 | 4 | 2018 |
| Osimertinib vs standard of care (SoC) EGFR-TKI as first-line treatment in patients with EGFR-TKI sensitising mutation (EGFRm) positive advanced non-small cell lung cancer … BC Cho, B Chewaskulyong, KH Lee, A Dechaphunkul, V Sriuranpong, ... Annals of Oncology 28, x190, 2017 | 3 | 2017 |
| Phase III trial comparing irinotecan plus cisplatin (IP) with etoposide plus cisplatin (EP) in Korean patients with extensive disease (ED) small cell lung cancer (SCLC) DW Kim, HG Kim, JH Kim, K Park, HK Kim, JS Jang, BS Kim, JH Kang, ... JOURNAL OF THORACIC ONCOLOGY 8, S219-S220, 2013 | 3 | 2013 |
| Brigatinib (BRG) vs Crizotinib (CRZ) in Patients (Pts) With ALK Inhibitor-Naive Advanced ALK+ NSCLC from ALTA-1L JCH Yang, HR Kim, MJ Ahn, JY Han, MJ Hochmair, KH Lee, A Delmonte, ... Annals of Oncology 30, vi83, 2019 | 1 | 2019 |
| OA11 First-Line Nivolumab+ Ipilimumab in Asian Patients With Advanced NSCLC and High TMB (≥ 10 mut/Mb): Results From CheckMate 227 K Park, J Lee, H Sakai, K Lee, Y Ohe, S Kim, T Fukuhara, J Kang, C Yu, ... Journal of Thoracic Oncology 13 (12), S1048, 2018 | 1 | 2018 |
| Trastuzumab deruxtecan (T-DXd, DS-8201) in HER2-positive metastatic breast cancer previously treated with T-DM1: DESTINY-Breast01 Study I Krop, C Saura Manich, T Yamashita, YH Park, SBK Kim, K Tamura, ... SWISS MEDICAL WEEKLY, 25S-25S, 2020 | | 2020 |
